Hefei Lifeon Pharmaceutical Co., Ltd.
SZSE:003020 Rapport sur les actions
Capitalisation boursière : CN¥3.9b
Ajouter à la liste de surveillanceHefei Lifeon Pharmaceutical Croissance future
Future contrôle des critères 3/6 Hefei Lifeon Pharmaceutical devrait augmenter ses bénéfices et son chiffre d'affaires de 24.6% et de 17.7% par an respectivement. Le BPA devrait croître de de 24.8% par an. Le rendement des capitaux propres devrait être 13.5% dans 3 ans.
Informations clés
24.6%
Taux de croissance des bénéfices
24.8%
Taux de croissance du BPA
Pharmaceuticals croissance des bénéfices 19.5% Taux de croissance des recettes 17.7% Rendement futur des capitaux propres 13.5% Couverture par les analystes Low
Dernière mise à jour 26 Sep 2024
Mises à jour récentes de la croissance future
Afficher toutes les mises à jour
Why Hefei Lifeon Pharmaceutical's (SZSE:003020) Shaky Earnings Are Just The Beginning Of Its Problems Nov 05
Third quarter 2024 earnings released: EPS: CN¥0.23 (vs CN¥0.22 in 3Q 2023) Oct 30
Hefei Lifeon Pharmaceutical (SZSE:003020) Has A Somewhat Strained Balance Sheet Sep 30
Hefei Lifeon Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024 Sep 30
Investor sentiment improves as stock rises 19% Sep 30
Second quarter 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.34 in 2Q 2023) Aug 31
Hefei Lifeon Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024 Jun 29
Hefei Lifeon Pharmaceutical (SZSE:003020) Has Announced A Dividend Of CN¥0.50 May 23
Dividend of CN¥0.50 announced May 23
Investors Still Aren't Entirely Convinced By Hefei Lifeon Pharmaceutical Co., Ltd.'s (SZSE:003020) Earnings Despite 25% Price Jump May 22
Hefei Lifeon Pharmaceutical's (SZSE:003020) Profits May Not Reveal Underlying Issues Apr 29
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 24
Hefei Lifeon Pharmaceutical Co., Ltd., Annual General Meeting, May 14, 2024 Apr 23
Investor sentiment improves as stock rises 16% Apr 23
Hefei Lifeon Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024 Mar 30
Investor sentiment deteriorates as stock falls 18% Feb 02
Hefei Lifeon Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024 Dec 29
Hefei Lifeon Pharmaceutical Co., Ltd. Approves Election of Shi Jing as an Independent Director Nov 18
Third quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.46 in 3Q 2022) Nov 01
Investor sentiment improves as stock rises 18% Oct 30
New minor risk - Share price stability Oct 23
Hefei Lifeon Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023 Sep 30
Second quarter 2023 earnings released: EPS: CN¥0.41 (vs CN¥0.33 in 2Q 2022) Aug 29
Investor sentiment deteriorates as stock falls 16% Aug 03
Hefei Lifeon Pharmaceutical Co., Ltd. Declares Cash Dividend on A Shares for 2022, Payable on May 24, 2023 May 18
Hefei Lifeon Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023 May 12
First quarter 2023 earnings released: EPS: CN¥0.54 (vs CN¥0.39 in 1Q 2022) Apr 18
Investor sentiment improves as stock rises 18% Feb 28
Third quarter 2022 earnings released: EPS: CN¥0.59 (vs CN¥0.35 in 3Q 2021) Oct 31
Investor sentiment improved over the past week Oct 18
Hefei Lifeon Pharmaceutical Co., Ltd. Announces Board Appointments Sep 01
Second quarter 2022 earnings released: EPS: CN¥0.43 (vs CN¥0.35 in 2Q 2021) Aug 29
Hefei Lifeon Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2021R May 17
Hefei Lifeon Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2021 May 12
First quarter 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.45 in 1Q 2021) Apr 29
No independent directors Apr 27
Hefei Lifeon Pharmaceutical Co. Proposes Final Cash Dividend for 2021 Apr 20
Full year 2021 earnings released: EPS: CN¥1.86 (vs CN¥1.94 in FY 2020) Apr 19
Third quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.49 in 3Q 2020) Oct 26
Second quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.53 in 2Q 2020) Aug 18
Investor sentiment deteriorated over the past week Jul 27
Investor sentiment improved over the past week Jun 02
Investor sentiment improved over the past week May 18
Hefei Lifeon Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2020 May 14
First quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.47 in 1Q 2020) Apr 28
Full year 2020 earnings released: EPS CN¥1.94 (vs CN¥1.51 in FY 2019) Apr 09
Hefei Lifeon Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 09, 2021 Feb 24
Investor sentiment deteriorated over the past week Jan 13
Investor sentiment deteriorated over the past week Dec 25
Prévisions de croissance des bénéfices et des revenus SZSE:003020 - Estimations futures des analystes et données financières antérieures (CNY Millions ) Date Recettes Les revenus Flux de trésorerie disponible Cash from Op Moy. Nombre d'analystes 12/31/2026 2,206 306 N/A 386 1 12/31/2025 1,833 242 N/A 302 1 12/31/2024 1,551 196 N/A 155 1 9/30/2024 1,501 174 106 268 N/A 6/30/2024 1,402 173 42 222 N/A 3/31/2024 1,423 191 12 198 N/A 12/31/2023 1,901 227 6 204 N/A 9/30/2023 2,210 210 -117 138 N/A 6/30/2023 2,618 242 -144 129 N/A 3/31/2023 2,763 228 -48 208 N/A 1/1/2023 2,579 209 -46 201 N/A 9/30/2022 2,503 217 -2 167 N/A 6/30/2022 2,429 187 64 249 N/A 3/31/2022 2,353 178 -48 165 N/A 12/31/2021 2,273 172 -28 159 N/A 9/30/2021 2,183 161 -41 134 N/A 6/30/2021 2,076 153 -7 115 N/A 3/31/2021 1,991 148 91 163 N/A 12/31/2020 1,894 135 116 172 N/A 9/30/2020 1,809 127 161 205 N/A 6/30/2020 1,758 120 158 201 N/A 3/31/2020 1,711 109 100 143 N/A 12/31/2019 1,650 105 105 149 N/A 12/31/2018 1,425 92 35 64 N/A 12/31/2017 1,167 77 N/A 11 N/A 12/31/2016 1,028 67 N/A 59 N/A 12/31/2014 962 54 N/A 92 N/A 12/31/2013 878 47 N/A 36 N/A
Afficher plus
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 003020 ( 24.6% par an) est supérieure au taux d'épargne ( 2.8% ).
Bénéfices vs marché: Les bénéfices de 003020 ( 24.6% par an) devraient croître plus lentement que le marché CN ( 26.4% par an).
Croissance élevée des bénéfices: Les bénéfices de 003020 devraient augmenter de manière significative au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de 003020 ( 17.7% par an) devrait croître plus rapidement que le marché CN ( 14% par an).
Croissance élevée des revenus: Le chiffre d'affaires de 003020 ( 17.7% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de 003020 devrait être faible dans 3 ans ( 13.5 %).
Découvrir les entreprises en croissance Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}